{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:14:25Z","timestamp":1791501265937,"version":"4.3.4"},"reference-count":26,"publisher":"Uppsala Medical Society","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Upsala Journal of Medical Sciences"],"published-print":{"date-parts":[[2018,7,3]]},"DOI":"10.1080\/03009734.2018.1489918","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T10:48:12Z","timestamp":1533638892000},"page":"174-178","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Desloratadine and depression, a drug safety signal based on worldwide spontaneous reporting of side effects"],"prefix":"10.48101","volume":"123","author":[{"given":"Jeltje","family":"Boer","sequence":"first","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, \u2019s-Hertogenbosch, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Ederveen","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, \u2019s-Hertogenbosch, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2799-9374","authenticated-orcid":false,"given":"Birgitta","family":"Grundmark","sequence":"additional","affiliation":[{"name":"Uppsala Monitoring Centre, Uppsala, Sweden;"},{"name":"Department of Surgery, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"28163","published-online":{"date-parts":[[2018,8,7]]},"reference":[{"key":"CIT0001","unstructured":"Summary of products characteristics for desloratadine (Azomyr\u00ae) [Internet]. European Medicines Agency; 2006 [cited 2017 Jun 28]. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000310\/WC500030164.pdf"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61566-9"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.2223\/JPED.1552"},{"key":"CIT0004","volume-title":"Goodman & Gilman\u2019s The pharmacological basis of therapeutics","author":"Brunton LL","year":"2006","edition":"11"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936050-00003"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.116.188078"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.3109\/03009730903572057"},{"key":"CIT0008","first-page":"210","volume-title":"Koster van Groos GAS, translator","author":"American Psychiatric Association","year":"2000","edition":"4"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031912-114409"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09298"},{"key":"CIT0011","unstructured":"Product label for desloratadine (Clarinex\u00ae) [Internet]. US Food and Drug Administration; 2014 [cited 2017 Jun 28]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021165s017,021300s014,021312s015,021563s003lbl.pdf"},{"key":"CIT0012","doi-asserted-by":"crossref","unstructured":"Summary of products characteristics for loratadine (Claritine\u00ae) [Internet]. Swissmedic Schweizerisches Heilmittelinstitut; 2017 Jan [cited 2017 Sep 19]. Available at: http:\/\/www.swissmedicinfo.ch\/default.aspx","DOI":"10.4414\/saez.2018.17387"},{"key":"CIT0013","unstructured":"Product label for loratadine (Claritin\u00ae) [Internet]. US Food and Drug Administration; 2000 [cited 2017 Aug 23]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2000\/20641s7lbl.pdf"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.2165\/11594320-000000000-00000"},{"key":"CIT0015","volume-title":"WHO Global Individual Case Safety Reports database","author":"VigiBase","year":"2017"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0594-2"},{"key":"CIT0017","unstructured":"Guideline on good pharmacovigilance practices (GVP). Module VI \u2013 Management and reporting of adverse reactions to medicinal product [Internet]. European Medicines Agency; 2014 Sep [cited 2017 Sep 14]. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/09\/WC500172402.pdf"},{"key":"CIT0018","unstructured":"Summary of product characteristics for montelukast [Internet]. Electronic Medicines Compendium; 2017 Jan [cited 2017 Nov 10]. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/28220"},{"key":"CIT0019","unstructured":"Summary of product characteristics for triamcinolone [Internet]. Electronic Medicines Compendium; 2017 Oct [cited 2017 Nov 12] Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/28913"},{"key":"CIT0020","unstructured":"Summary of product characteristics for paroxetine [Internet]. Electronic Medicines Compendium; 2016 Mar [cited 2017 Nov 12]. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/26965"},{"key":"CIT0021","volume-title":"Stockley\u2019s Drug Interactions [Internet]","author":"Baxter K","year":"2017"},{"key":"CIT0022","unstructured":"Bonin L. Pediatric unipolar depression: epidemiology, clinical features, assessment, and diagnosis [Internet]. Waltham (MA): UpToDate; 2017 [cited 2017 Nov 12]. Available at: https:\/\/www.uptodate.com\/contents\/pediatric-unipolar-depression-epidemiology-clinical-features-assessment-and-diagnosis [access restricted]."},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932020-00009"},{"key":"CIT0024","first-page":"445","volume":"12","author":"Gonz\u00e1lez-N\u00fa\u00f1ez V","year":"2013","journal-title":"Drug Saf"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.3109\/13651501.2014.907919"},{"key":"CIT0026","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA) [Internet]. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. [cited 2018 Apr 27]. Available at: https:\/\/www.meddra.org\/"}],"container-title":["Upsala Journal of Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03009734.2018.1489918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T21:36:10Z","timestamp":1611264970000},"score":1,"resource":{"primary":{"URL":"https:\/\/ujms.net\/index.php\/ujms\/article\/view\/5808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,8,8]]},"published-print":{"date-parts":[[2018,7,3]]}},"alternative-id":["10.1080\/03009734.2018.1489918"],"URL":"https:\/\/doi.org\/10.1080\/03009734.2018.1489918","relation":{},"ISSN":["0300-9734","2000-1967"],"issn-type":[{"value":"0300-9734","type":"print"},{"value":"2000-1967","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iups20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iups20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}